Fig. 1
From: Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?
The roles of BCL-6 and EZH2 in CD4+ T cells. BCL-6 can inhibit miR-142-3p/5p expression by recruiting EZH2 and HDAC5 to the miR-142 promoter, which results in the upregulation of H3K27me3 and the downregulation of H3K9/K14ac, and inhibition of miR-142-3P/5P increases IL-21 production. IL-21 upregulates the transcription levels of BCL-6 by increasing TET2 levels in the promoter of BCL-6. E4BP4 or UHRF1 increase H3K27me3 levels in the promoter of BCL-6 by recruiting EZH2. After EZH2 phosphorylation at Ser21, EZH2 can be recruited by TCF1 to directly activate BCL-6 transcription
